Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hedge Fund News: Jeffrey Smith, Chris Hohn & Lansdowne Partners

Page 1 of 2

Starboard Succeeds in Replacing Entire Darden Board (WSJ)
Starboard Value LP succeeded in replacing the entire board of Darden Restaurants, Inc. (NYSE:DRI) +0.18% according to a preliminary count of the vote of shareholders, the company said Friday. The New York hedge fund, which owns 8.8% of Darden and is the company’s second-biggest shareholder, will have two of its own partners on the board along with 10 other directors it nominated. The new board has several restaurant-industry veterans, including Bradley Blum, who was previously president of Olive Garden. Starboard Chief Executive Jeffrey Smith, who is one of the hedge fund’s two representatives on the board, said in a statement that the new board is “excited” to get to work.

Jeff Smith

Northern Trust provides hedge fund administration to BlueHive Capital (HedgeWeek)
As part of the broad mandate, Northern Trust will also provide depositary services. “We selected Northern Trust Hedge Fund Services for its industry-leading technology and commitment to transparency,” says Sebastien Boucher, chief investment officer and founder of BlueHive Capital. “Whether it’s providing more transparency to investors or complying with regulatory requirements, the demand for data is growing and Northern Trust’s innovative technology solutions help us to meet those demands.” Based in Paris, BlueHive Capital was launched by former Natixis CIB’s global alpha team…

Third Point Among Biggest DSM Owners, Pushes Nutrition (BusinessWeek)
U.S. activist investor Third Point LLC, which has asked Dutch chemical maker Royal DSM NV (DSM) to focus on nutritional additives, is now the company’s third-biggest shareholder. The New York-based hedge fund, which helped push The Dow Chemical Company (NYSE:DOW) in the U.S. to divest assets, now owns a 3.004 percent stake, according to a regulatory filing last week. While DSM has resisted shareholder calls to divest its 4.3 billion-euro ($5.5 billion) legacy plastics and chemicals units, the company has in recent weeks advanced efforts to sell part of them, according to people familiar with the matter.

Finisterre Hires Barclays Vet As Credit Research Chief (Finalternatives)
Finisterre Capital has named its first head of credit research, bolstering its capabilities in fixed-income. The London-based hedge fund named Christopher Buck to fill the role. Buck joins the US$2.6 billion firm from Barclays Capital, where he was head of Latin America corporate credit research. “The institutional inflows over the last year have emphasized our ability to deliver alpha for our clients in a format that meets their needs,” Finisterre co-founder Paul Crean said. “During this period, we have been consistently looking to expand our team.”

Computer-Driven Programs Reboot in Choppy Market (InstitutionalInvestorsAlpha)
It looks like this year’s commodity trading adviser rally is for real, as 2014 is shaping up to be the best year for computer-driven hedge funds since 2008. Most of these funds, which are the computer-driven siblings of human-driven macro funds, extended their gains in September and are easily beating the equity indexes, underscoring once again that CTAs are not closely correlated with the stock market. Of course, this has been a bitter reality since the stock market’s rally began in March 2009, as many CTAs and trend followers have generated one or more losing years.

Cramer: Hedge funds imploding (CNBC)

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!